NCT01146561 - Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2010

Primary Completion Date

March 22, 2011

Study Completion Date

March 22, 2011

Conditions

Chronic Pancreatitis

Interventions

BIOLOGICAL

Tanezumab

single administration of tanezumab 20 mg sub-cutaneously

OTHER

Placebo

single administration of placebo to match tanezumab, sub-cutaneously

Trial Locations (9)

UMPC Division of Radiology, Pittsburgh

University of Pittsburgh Medical Center, Pittsburgh

Carolinas Digestive Health Associates, Harrisburg

Carolinas Digestive Health Associates, Harrisburg

Palm Beach Gastroenterology, Wellington

Digestive Health Specialists, Tupelo

North Mississippi Medical Center, Tupelo

Wisconsin Center for Advanced Research, Milwaukee

Gastroenterology Group-of Naples, Naples